IP Library › Granted Patent US 10,816,552
Granted Patent B2
US 10,816,552 · App. 16/245,328 · Granted Oct 27, 2020

Organotellurium compounds, compositions and methods of use thereof

Inventors: Mark Nitz (Toronto, CA); Landon J. Edgar (Midhurst, CA); Bradly G. Wouters (Toronto, CA); David Hedley (Toronto, CA); Lisa M. Willis (Toronto, CA); Matthew A. Lumba (Toronto, CA); Hanuel Park (London, CA); Ravi N. Vellanki (Toronto, CA)
Assignees: The Governing Council of the University of Toronto; University Health Network
G01N33/58C07D345/00C07D421/06C07H15/04G01N33/569G01N2458/15G01N2560/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,816,552
App. No.
16/245,328
Granted
Oct 27, 2020
Kind
B2
Abstract

A compound of formula (I): as described herein and methods and uses thereof as for mass tagging a biosensor or biologically active material.

Claims (41)

1. A compound of formula (II):

wherein

A is a naturally occurring isotope of Te;

R 1 is selected from H, unsubstituted or substituted C 1 -C 20 alkyl, unsubstituted or substituted C 3 -C 20 cycloalkyl, unsubstituted or substituted aryl and an electron withdrawing group;

L is C 1-20 alkylene, unsubstituted or substituted with one or more substituents, and/or optionally interrupted with one or more heteromoieties independently selected from O, S, NR 7 , and/or optionally interrupted with one or more of C(O) and C(S);

R 7 is independently selected from H, protecting group (PG) and C 1-6 alkyl; and

Z is a biologically active material and/or a salt and/or solvate thereof, wherein the biologically active material is selected from polypeptide, nucleic acid, peptidic nucleic acid, oligosaccharide, polysaccharide lipopolysaccharide, hormone, pharmacologically active substance, steroid, vitamin, amino acid and sugar, preferably wherein the biologically active material is selected from an affinity reagent selected from an antibody or binding fragment thereof, aptamer, avidin reagent, nucleic acid or lectin.

2. The compound of claim 1 ,

wherein R 1 is an electron withdrawing group selected from selected from C(O)R 2 , C(R 3 ) 3 , C≡N, and NO 2 , wherein

R 2 is selected from H and C 1-6 alkyl; and

R 3 is halo;

wherein the substituents on R 1 are independently selected from one or more of halo, C1-6 alkyl and C 1-6 alkoxy;

wherein the substituents on L are independently selected from halo, C 1-6 alkyl, C 1-6 alkoxy, C(O)R 4 and NR 5 R 6 , wherein R 4 is selected from H and C 1-6 alkyl and R 5 and R 6 are independently selected from H, PG, C(O)C 1-20 alkyl and C(O)OC 1-20 alkyl;

wherein R 1 is selected from H, unsubstituted or substituted C 1-10 alkyl, unsubstituted or substituted C 3 -C 10 cycloalkyl, unsubstituted or substituted phenyl and an electron withdrawing group selected from C(O)R 2 and C(R 3 ) 3 ;

the substituents on R 1 are independently selected from one or more of halo and C 1-3 alkyl;

R 2 is selected from H and C 1-6 alkyl; and

R 3 is F, Cl, Br, and I, preferably wherein R 1 is selected from H and C(R 3 ) 3 wherein R 3 is F, optionally wherein R 1 is H;

wherein L is a C 1-25 alkylene, unsubstituted or substituted with one or more substituents independently selected from C 1-3 alkyl, C(O)R 4 and NR 5 R 6 , and/or optionally interrupted with one or more heteromoieties independently selected from O and NR 7 , and/or optionally interrupted with C(O);

R 4 is selected from H and C 1-2 alkyl;

R 5 and R 6 are independently selected from H, PG, C(O)C 1-6 alkyl and C(O)OC 1-6 alkyl; and

R7 is independently selected from H and PG.

3. The compound of claim 1 , wherein

L is a C 1-25 alkylene, unsubstituted or substituted with one or more substituents independently selected from NR 5 R 6 , and/or optionally interrupted with one or more heteromoieties independently selected from 0 and NR 7 , and/or optionally interrupted with C(O);

R 5 and R 6 are independently selected from H, PG, and C(O)OC 1-4 alkyl; and

R 7 is H.

4. The compound of claim 1 , wherein the compound is compatible with biological systems.

5. The compound of claim 4 , wherein the compound is non-toxic.

6. The compound of claim 1 , wherein the biologically active material is an amino acid.

7. The compound of claim 6 , wherein the amino acid is phenylalanine or an analog thereof.

8. The compound of claim 6 , wherein the compound is incorporated into a biomolecule target analyte.

9. The compound of claim 6 , wherein the compound is for incorporation into a biomolecule target analyte.

10. The compound of claim 9 , wherein the biomolecule target analyte is a protein.

11. The compound of claim 1 , wherein the biologically active material is a nucleic acid.

12. The compound of claim 1 , wherein the biologically active material is an antibody or binding fragment thereof.

13. A kit comprising a compound of formula (II):

wherein

A is a naturally occurring isotope of Te;

R 1 is selected from H, unsubstituted or substituted C 1 -C 20 alkyl, unsubstituted or substituted C 3 -C 20 cycloalkyl, unsubstituted or substituted aryl and an electron withdrawing group;

L is C 1-20 alkylene, unsubstituted or substituted with one or more substituents, and/or optionally interrupted with one or more heteromoieties independently selected from O, S, NR 7 , and/or optionally interrupted with one or more of C(O) and C(S);

R 7 is independently selected from H, protecting group (PG) and C 1-6 alkyl; and

Z is a biologically active material and/or a salt and/or solvate thereof, wherein the biologically active material is selected from polypeptide, nucleic acid, peptidic nucleic acid, oligosaccharide, polysaccharide lipopolysaccharide, hormone, pharmacologically active substance, steroid, vitamin, amino acid and sugar, preferably wherein the biologically active material is selected from an affinity reagent selected from an antibody or binding fragment thereof, aptamer, avidin reagent, nucleic acid or lectin.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2019
From: NITZ, MARK; EDGAR, LANDON; WILLIS, LISA; LUMBA, MATTHEW; PARK, HANUEL
To: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
Reel/Frame 048399/0545 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2019
From: HEDLEY, DAVID W.; WOUTERS, BRADLY G.; VELLANKI, RAVI N.
To: UNIVERSITY HEALTH NETWORK
Reel/Frame 048399/0572 →
Continuity (4)
Continuation 15505197
Provisional Application 62165002 · May 21, 2015
Provisional Application 62039762 · Aug 20, 2014
Related Publication 20190250165A1 · Aug 15, 2019